$1.39
1.07% day before yesterday
Nasdaq, May 30, 09:48 pm CET
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

PDS Biotechnology Corp. Stock price

$1.38
-0.02 1.43% 1M
-0.77 35.81% 6M
-0.25 15.34% YTD
-1.57 53.22% 1Y
-4.00 74.35% 3Y
+0.16 13.11% 5Y
-257.42 99.47% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.02 1.43%
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

Key metrics

Market capitalization $63.08m
Enterprise Value $42.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.80
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-35.33m
Free Cash Flow (TTM) Free Cash Flow $-34.12m
Cash position $39.98m
EPS (TTM) EPS $-0.87
P/E forward negative
Short interest 6.49%
Show more

Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

PDS Biotechnology Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a PDS Biotechnology Corp. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a PDS Biotechnology Corp. forecast:

Buy
100%

Financial data from PDS Biotechnology Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
10% 10%
-
- Research and Development Expense 22 22
24% 24%
-
-35 -35
19% 19%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -35 -35
19% 19%
-
Net Profit -36 -36
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PDS Biotechnology Corp. Stock News

Neutral
GlobeNewsWire
12 days ago
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat during the Alliance Global P...
Positive
Proactive Investors
18 days ago
PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts.
More PDS Biotechnology Corp. News

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Head office United States
CEO Frank Bedu-Addo
Employees 24
Founded 2005
Website www.pdsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today